When AI designs a drug, who gets the credit?
Insilico Medicine's AI platform identified a drug candidate for pulmonary fibrosis, which the company credited entirely to its generative AI system in announcements. The situation highlights ambiguity about attribution when AI systems propose drug molecules that humans might not independently discover.
Read full story →Anthropic Brings Claude Mythos 5 to Claude Security: Enterprise Teams Get Frontier Vulnerability Scanning Without Direct Model Access
Claude Security now runs on Claude Mythos 5 and scans GitHub repositories for vulnerabilities without requiring separate model access. The tool traces data flows across files and returns findings with CWE categories, confidence and severity ratings, plus suggested patches.
WhiteFiber Closes $310M Convertible Notes to Fund Data Center Expansion
WhiteFiber closed a $310 million convertible notes offering on August 21, 2026, netting approximately $298.5 million in proceeds. The company allocated roughly $180 million toward data center expansion after using $118.5 million to exchange existing convertible debt.
Anthropic Deploys Claude Mythos 5 in Security Tools, $35M Open-Source Fund
Claude Mythos 5, a cyber-capable model previously limited to vetted defenders since April 2026, now runs vulnerability scans in Claude Security for Enterprise customers. Anthropic committed $35 million in credits to a new open-source defense fund and plans to expand its Cyber Verification Program for broader access to Mythos-class models.